Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure

Acta Pharmacologica Sinica

Volumn 27, Issue 11, 2006, Pages 1417-1422

  Xia, Qin Gui ^a,b   Reinecke, Alexander ^b   Dorenkamp, Marc ^b   Daemen, Mat Jap ^c   Simon, Reichiger ^b   Unger, Thomas ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF KIEL   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiac remodeling; Endothelin ETA receptor antagonism; Heart failure; LU 135252; Myocardial infarction; SHR SP rats; Ventricular function

Indexed keywords

DARUSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIN A RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEART WEIGHT; HEMODYNAMICS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; SURVIVAL RATE; ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; HEART MUSCLE; HEART VENTRICLE REMODELING; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BLOOD PRESSURE; HEART FAILURE; HEART RATE; HYPERTENSION; MALE; MYOCARDIUM; ORGAN SIZE; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, INBRED SHR; RECEPTOR, ENDOTHELIN A; VENTRICULAR REMODELING;

EID: 33750356659     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00447.x     Document Type: Article

References (19)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998; 332: 411-5.
2. B receptor blockade. Circulation 1999; 100: 5-8.
3. Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci 1993; 84: 427-33.
4. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-84.
5. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in congestive heart failure. Circulation 1992; 85: 1374-9.
6. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
7. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation 1997; 95: 1918-29.
8. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-5.
9. A receptor blockade prevent left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998; 39: 600-8.
10. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1&2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 4: 381-8.
11. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomised, double blind, placebo-controlled trial. Lancet 2004; 364: 347-54.
12. 1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res 2001; 49: 110-7.
13. Riechers H, Albrecht HP, Amber W, Baumann E, Bernard H, Bohm HJ, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996; 39: 2123-8.
14. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001; 103: 313-8.
15. Booz GW, Baker KM. Molecular singling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995; 30: 537-43.
16. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27: 2130-4.
17. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, et al. Role of endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-82.
18. Mebezaa A, Mayoux E, Maeda K. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am J Physiol 1993; 265: H1841-6.
19. Kasai H, Takanashi M, Takasaki C, Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol 1994; 266: H2220-8.